Future Oncology

Journal

Publication Venue For

  • BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.  18:3245-3254. 2022
  • POLARIS: A prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor-positive advanced breast cancer.  16:2475-2485. 2020
  • Copanlisib in the treatment of non-Hodgkin lymphoma.  16:1947-1955. 2020
  • Effects of center type and socioeconomic factors on early mortality and overall survival of diffuse large B-cell lymphoma.  15:2113-2124. 2019
  • Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.  15:3267-3281. 2019
  • Second primary malignancy in acute promyelocytic leukemia: A Surveillance, Epidemiology and End Results database study.  13:1455-1457. 2017
  • Leukemic transformation in patients with myeloproliferative neoplasms: A population-based retrospective study.  13:1239-1246. 2017
  • Induction chemotherapy for head and neck cancer: Is there still a role?.  12:1595-1608. 2016
  • L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.  11:2459-2470. 2015
  • Enhancing cancer care in areas of limited resources: our next steps..  10:1953-1965. 2014
  • Tivozanib for the treatment of renal cell carcinoma: Results and implications of the TIVO-1 trial.  10:1819-1826. 2014
  • Inactivation of X-linked tumor suppressor genes in human cancer.  8:463-481. 2012
  • Mechanisms of cancer cell metastasis to the bone: A multistep process.  7:1285-1297. 2011
  • Cilengitide: An RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies.  7:339-354. 2011
  • TRAIL-receptor antibodies as a potential cancer treatment.  3:405-409. 2007
  • Understanding racial differences in colorectal cancer aids in individualized medicine.  3:235-241. 2007
  • TRAIL receptor-targeted therapy.  2:493-508. 2006
  • Cancer scene investigation: How a cold virus became a tumor killer.  1:247-258. 2005

    • International Standard Serial Number (issn)

  • 1479-6694

    • Electronic International Standard Serial Number (eissn)

  • 1744-8301